Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TFBS BioscienceROCO:6939 +3.56%54 5-Year Yield-on-Cost % is 0.00 as of Aug. 26, 2026. GuruFocus rates ROCO:6939 with a GF Score™ of 54/100 and a GF Value™ of NT$29.93 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, TFBS Bioscience ranks worse than 1612901.61% on this metric.
TFBS Bioscience's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for TFBS Bioscience's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 6 years, TFBS Bioscience's highest Yield on Cost was 0.35. The lowest was 0.00. And the median was 0.23.
ROCO:6939's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.44 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TFBS Bioscience 5-Year Yield-on-Cost % Related Terms
ROCO:6939 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, TFBS Bioscience's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TFBS Bioscience 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TFBS Bioscience's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of TFBS Bioscience is calculated as
TFBS Bioscience (ROCO:6939) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TFBS Bioscience and its competitors. According to the industry distribution chart, TFBS Bioscience ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is TFBS Bioscience's 5-Year Yield-on-Cost % too high?
TFBS Bioscience's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, TFBS Bioscience ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, TFBS Bioscience has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TFBS Bioscience's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, TFBS Bioscience ranks #999999 out of 62 companies for 5-Year Yield-on-Cost %. This places TFBS Bioscience in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.44, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TFBS Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TFBS Bioscience's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TFBS Bioscience stock overvalued right now?
Based on GuruFocus' analysis, TFBS Bioscience (ROCO:6939) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.93, compared to a current price of NT$20.35 — trading 32% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. TFBS Bioscience's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TFBS Bioscience (ROCO:6939), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TFBS Bioscience (ROCO:6939) Overvalued in 2026?
Based on GuruFocus' analysis, TFBS Bioscience stock appears to be undervalued.
The current stock price of NT$20.35 is trading 32% below its estimated GF Value™ of NT$29.93.
GuruFocus considers TFBS Bioscience to be Possible Value Trap.
Key valuation signals for ROCO:6939:
5-Year Yield-on-Cost %: 0.00
GF Value™: NT$29.93 vs. price of NT$20.35 (32% below fair value)
No single metric tells the full story. See the ROCO:6939 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
54GF Score
Get the complete analysis for ROCO:6939
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6939 has been successfully added to your 
